ARCHIVES

Letter to the Editor: Expanding the Horizons Of Proton Beam Therapy

This article is from The Cancer Letter archive.

Vol. 40 No. 31 | August 1, 2014

Download PDF Visit The Full Archive

Related Articles

Two Phase II Trials Display Ramucirumab Potential Efficacy

October 26, 2012

In Brief: Harmon Eyre Heads Medical Affairs, Research As Third Member OF ACS National Office “Troika”

April 16, 1993

NCI Advisory Group, Other Cancer Meetings For September, October

August 27, 1976

Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit

March 30, 2012

Interview With Departing NCI Director; Advice To His Successor.

July 9, 2010

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012